

PATENT
Customer No. 22,852
Attorney Docket No. 2356.0085

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Pierre DRUILHE) Group Art Unit: Not assigned
)
Application No.: 10/691,672) Examiner: Not assigned
)
Filed: November 12, 2003)
)
For: GLURP-MSP3 FUSION PROTEIN,)
IMMUNOGENIC COMPOSITIONS)
AND MALARIAL VACCINES)
CONTAINING IT)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: February 26, 2004


By: 
Kenneth J. Meyers
Reg. No. 25,146

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02356.0085	Appln. No.	10/691,672
Applicant	Pierre DRUILHE		
Filing Date	November 12, 2003	Group:	Not assigned



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	P. Druilhe, et al.; <i>In vivo veritas</i> : lessons from immunoglobulin-transfer experiments in malaria patients; <i>Annals of Tropical Medicine and Parasitology</i> , (1997) 91(1) pgs. S37-S53
	C. Oeuvray, et al.; A novel merozoite surface antigen of <i>Plasmodium falciparum</i> (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies, <i>Mem. Inst. Oswaldo Cruz</i> , Rio de Janeiro (1994) 89(II) pg. 77-80
	E. Badell, et al.; Human malaria in immunocompromised mice: an <i>in vivo</i> model to study defense mechanisms against <i>Plasmodium falciparum</i> , <i>J. Exp. Med.</i> (Dec. 2000) 192(11) pgs. 1653-1659
	M. Blackman, et al.; A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies, <i>J. Exp. Med.</i> (July 1990) Vol. 172, pgs. 379-382
	H. Bouharoun-Tayoun, et al.; Mechanisms underlying the monocyte-mediated antibody-dependent killing of <i>Plasmodium falciparum</i> Asexual blood stages, <i>J. Exp. Med.</i> (August 1995) Vol. 182, pgs. 409-418
	D. Doodoo, et al.; Levels of antibody to conserved parts of <i>Plasmodium falciparum</i> merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria; <i>Infect. and Immun.</i> (May 1999) 67(5) pgs. 2131-2137
	H. Israelsen et al.; Cloning and partial characterization of regulated promoters from <i>Lactococcus lactis</i> Tn917- <i>lacZ</i> integrants with the new promoter probe vector, pAK80, <i>Applied and Environmental Microbiology</i> , (July 1995) 61(7) pgs. 2540-2547
	S. Khusmith, P. Druilhe; Cooperation between antibodies and monocytes that inhibit <i>in vitro</i> proliferation of <i>Plasmodium falciparum</i> ; <i>Infect. and Immun.</i> (July 1983) 41(1) pgs. 219-223
	F. Lunel, P. Druilhe; Effector cells involved in nonspecific and antibody-dependent mechanisms directed against <i>Plasmodium falciparum</i> blood stages <i>in vitro</i> ; <i>Infect. and Immun.</i> (July 1989) 57(7) pgs. 2043-2049
	V. Marshall et al.; Close linkage of three merozoite surface protein genes on chromosome 2 of <i>Plasmodium falciparum</i> ; <i>Molecular and Biochemical Parasitology</i> (1998) Vol. 94, pgs. 13-25

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02356.0085	Appln. No.	10/691,672
Applicant	Pierre DRUILHE		
Filing Date	November 12, 2003	Group:	Not assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	D. McColl, R.Anders; Conservation of structural motifs and antigenic diversity in the <i>Plasmodium falciparum</i> merozoite surface protein-3 (MSP-3); Molecular and Biochemical Parasitology, (1997) Vol. 90, pgs. 21-31
	C. Oeuvray et al.; Merozoite surface protein-3: a malaria protein inducing antibodies that promote <i>Plasmodium falciparum</i> killing by cooperation with blood monocytes; Blood (September 1994) 84(5), pgs. 1594-1602
	C. Oeuvray et al.; Cytophilic immunoglobulin responses to <i>Plasmodium falciparum</i> glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal, Infect. and Immun. (May 2000) 68(5) pgs. 2617-2620
	R. Pleass, J.Woof; Fc receptors and immunity to parasites; Trends I Parasitology (November 2001) 17(11) pgs. 545-551
	M. Theisen et al.; The glutamate-rich protein (GLURP) of <i>Plasmodium falciparum</i> is a target for antibody-dependent monocyte-mediated inhibition of parasite growth <i>in vitro</i> ; Infect. and Immun. (Jan. 1998) 66(1) pgs. 11-17

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce